文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT可避免胰腺导管腺癌无效手术并揭示肿瘤生物学

68Ga-FAPI PET/CT Prevents Futile Surgery and Demonstrates Tumor Biology in Patients with Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · J Nucl Med · 2025-12-03

该研究纳入标准CT评估可手术的胰腺导管腺癌患者,术前行68Ga-FAPI PET/CT并随访至治疗意图确认。16例中5例(31%)检出CT未见的转移而避免手术,原发灶SUVmax与淋巴结比率相关(P=0.04)。

要点

  • 68Ga-FAPI PET/CT在31%的可手术PDAC患者中检出CT隐匿转移,避免无效手术。
  • 原发灶60分钟SUVmax与切除肿瘤淋巴结比率相关(P=0.04),提示可反映肿瘤生物学。
  • 仅当改变治疗意图时才因68Ga-FAPI PET/CT追加检查,未增加无谓探查。

核心结论

  • 68Ga-FAPI PET/CT可能改善胰腺导管腺癌的治疗选择。
  • 需开展对比性试验以确认其在临床实践中的作用。

研究设计与样本

  • 研究纳入标准CT评估为可手术候选者的胰腺导管腺癌患者,术前接受68Ga-FAPI PET/CT,随访至治疗意图确认。
  • 以切除肿瘤的淋巴结比率作为肿瘤生物学替代标志物,用线性回归与原发性肿瘤SUVmax进行相关性分析。
  • 共16例符合条件的参与者。

主要发现

  • 16例中5例(31%)存在CT未见但68Ga-FAPI PET/CT检出的转移,因而未行手术。
  • 2例68Ga-FAPI PET/CT未见转移的参与者在新生辅助治疗后因局部进展未行手术。
  • 原发性肿瘤60分钟SUVmax与切除PDAC的淋巴结比率相关(P=0.04)。
  • 除改变治疗意图外,68Ga-FAPI PET/CT未引发额外检查。

关键数值与推荐

  • 原发灶60分钟SUVmax与淋巴结比率线性回归相关,P=0.04。
  • 5/16(31%)参与者因68Ga-FAPI PET/CT检出CT隐匿转移而避免手术。

临床怎么用

  • 对标准CT评估可手术的PDAC患者,术前68Ga-FAPI PET/CT可检出隐匿转移,帮助避免无效手术。
  • 原发灶SUVmax可能作为肿瘤生物学的无创标志物,辅助治疗决策。
  • 仅在68Ga-FAPI PET/CT结果改变治疗意图时才追加其他检查。

局限性

  • 样本量小(16例),结论需对比性试验确认。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET/CT using 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) may detect occult metastases and identify aggressive tumor biology in patients with pancreatic ductal adenocarcinoma (PDAC). We evaluated the impact of 68Ga-FAPI PET/CT on surgical treatment in this patient population. Methods: Patients with PDAC who were deemed operative candidates after standard CT underwent pretreatment 68Ga-FAPI PET/CT and were followed until confirmation of treatment intent. Lymph node ratio in resected tumors was used as a surrogate marker for tumor biology and correlated with the SUVmax of the primary tumor using linear regression. Results: Of 16 eligible participants, 5 (31%) had metastases that were not visible on CT scans but were detected with 68Ga-FAPI PET/CT, and surgery was prevented. No additional investigations were prompted by 68Ga-FAPI PET/CT unless they changed treatment intent. Two participants without metastases on 68Ga-FAPI PET/CT did not have surgery because of local progression after neoadjuvant therapy. The SUVmax of the primary tumor at 60 min correlated with the lymph node ratio in resected PDAC (P = 0.04). Conclusion: 68Ga-FAPI PET/CT may enhance treatment selection in PDAC. Comparative trials are the next step to confirm role in the clinical setting.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. McGahan W, Chadwick A, Lindsay K, et al. 68Ga-FAPI PET/CT Prevents Futile Surgery and Demonstrates Tumor Biology in Patients with Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2025. PMID: 41067862. doi:10.2967/jnumed.125.270510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。